Cellevate participates at GLIA 2023 in Berlin, July 8-11 to promote Cellevat3d™ NanoMatrice™ – a neuro-scaffold designed for research of the central nervous system
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems, will be participating at the 16th European Meeting on Glial Cells in Health and Disease in Berlin, Germany, on July 8-11, 2023, focused on enhancing public awareness for the glial cells in the central nervous system, and for diseases related to glial cells. At the conference Cellevate aims to promote the life science research nanofiber-based platform, Cellevat3d™ NanoMatrice™, developed in the latest years in collaboration with researchers focusing on the areas of oncology, immunology, and neurodegenerative diseases. We are looking forward to meeting you at the conference and engage in discussions about our innovative Cellevat3d™ NanoMatrice™ products. We invite you to visit our Cellevate representatives at booth No. 6 and learn more.
One of Cellevate’s latest life science research applications is the Cellevat3d™ NanoMatrice™ Neuro platform in the neurodegenerative disease area, developed in collaboration with researchers at BioMed X Institute in Heidelberg, Germany. This platform is a valuable tool for studying myelination biology using human-derived cells and exploring diseases with myelin pathology like schizophrenia, multiple sclerosis, and autism. Protocols describing this application have been published in STAR protocols, Vol 4, Issue 2, June 16, 2023. In addition, one of the authors, Martina von der Bay, Doctoral Researcher at BioMed X Institute, and the researcher team will present a poster at the Berlin conference with the study results from our mutual collaboration:
Poster: T19-010A (#271)
Title: 3D co-culture platform to study myelination deficits in schizophrenia using hiPSC-derived neurons and oligodendrocyte lineage cells
Time: July 8, 2023, at 17:46
We are grateful to Martina von der Bey, Ebru Ercan-Herbst and all of team EPD at BioMed X Institute, for the experimental work. This study was supported by Boehringer Ingelheim Pharma GmbH & Co. KG.
For more information, please contact:
Laura Chirica, PhD
Cellevate is a spin out from NanoLund – a world leading nanomaterial academic center. The company founded in 2014, develops and already markets products based on a proprietary nanofiber-based platform – the Cellevat3d™ – a game-changing, green and sustainable, deep-tech innovation for life science research applications in neurology, immunology and oncology. This platform allows for an industrial-scale production of carriers with unparalleled surface area for cell growth, reproducibility and customization. Cellevat3d™ carrier products are designed for laboratory testing of cell lines as well as pilot and large-scale batch production of novel classes of biological therapies, including cell- and gene therapies and vaccines. Cellevat3d™ carriers have a commercial launch and sales start planned for 2024.
For more information, please visit www.cellevate.com.